Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can we predict dangerous blood clots in lymphoma patients? a major study aims to find out

NCT ID NCT06694779

Knowledge-focused Sponsor: Fondazione IRCCS San Gerardo dei Tintori Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 30, 2026 · Last updated Jul 01, 2026 · Updated 1 time

Summary

This study looks at how well existing risk models predict dangerous blood clots in people with diffuse large B-cell lymphoma (DLBCL), a common type of blood cancer. Researchers will review medical records from over 1,500 patients across multiple hospitals to see which factors are most linked to clots. The goal is to create a more accurate tool to help doctors decide who might benefit from clot-preventing medication.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could lead to a better way to identify lymphoma patients at high risk of blood clots, helping doctors decide who needs preventive treatment.
What could go wrong
This is an observational study, not a treatment trial, so it won't directly test any new drug or therapy. The findings may not change practice immediately.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

1,504 people

The number who actually took part.

Started

May 2023

Finished

May 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

-. Patients with a diagnosed of DLBCL from 01/01/2004 until 31/12/2022 can be enrolled in the study

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Subjects aged ≥ 18 years * Histological diagnosis of DLBCL * Informed consent freely given and obtained Exclusion Criteria: * Active anticoagulant therapy at the time of diagnosis * Start of prophylactic heparin following diagnosis * Absence of necessary data to extrapolate risk scores (Khorana, Throly and Model IX) at diagnosis

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Diffuse large B-cell lymphoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

diffuse large B-cell lymphoma thrombotic disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Diffuse large B-cell lymphoma Thrombosis

Contacts and locations

Locations

  • Ivan Civettini

    Monza, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.